Leslie Amass

Pfizer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

36h-index4.2kcitations95works3.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyloidosis: Diagnosis, Treatment, Outcomes(49), Opioid Use Disorder Treatment(22), Substance Abuse Treatment and Outcomes(20), Parathyroid Disorders and Treatments(20), Coagulation, Bradykinin, Polyphosphates, and Angioedema(11)

Publications95 total

A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary
Future Cardiology·2025Open Access
Real-world effectiveness of tafamidis in a contemporary, matched cohort of patients with variant and wild-type transthyretin amyloid cardiomyopathy
European Heart Journal·2025
Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis
European Heart Journal·2025
Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic Benefits
Cardiology and Therapy·2025· 5 citedOpen Access
Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS
Cardiology and Therapy·2025· 1 citedOpen Access
Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare: a plain language summary
Future Cardiology·2025Open Access
Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis
JACC Advances·2024· 10 citedOpen Access
Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Journal of Cardiac Failure·2024· 32 citedOpen Access
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy PC94 (#15)
2024
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy PC93 (#14)
2024
Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey PC149 (#8)
2024· 1 cited
Survival in a real-world cohort of patients with mixed phenotype transthyretin amyloidosis treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey PC107 (#10)
2024
A final, consolidated overview of 16 years of data from the Transthyretin Amyloidosis Outcomes Survey PB21 (#16)
2024
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy
Cardiology and Therapy·2024· 2 citedOpen Access
Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
PLoS ONE·2024· 8 citedOpen Access
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
Cardiology and Therapy·2023· 18 citedOpen Access
A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Orphanet Journal of Rare Diseases·2023· 52 citedOpen Access
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay
Amyloid·2023· 13 citedOpen Access
A natural history analysis of asymptomatic <i>TTR</i> gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Amyloid·2022· 24 citedOpen Access
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update
Orphanet Journal of Rare Diseases·2022· 83 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Warren K. Bickel(12), Márcia Waddington‐Cruz(11), Hartmut Schmidt(9), Isabel Conceição(8), Arnt V. Kristen(8), Mathew S. Maurer(8), Jonathan B. Kamien(7), Angela Dispenzieri(7), Jonas Wixner(7), Violaine Planté‐Bordeneuve(7), Doug Chapman(7), Fábio Barroso(6), Teresa Coelho(6), Claudio Rapezzi(6), José González‐Costello(6), Brian Drachman(6), Saša Živković(6), Stephen T. Higgins(5), Gary J. Badger(5), Olivier Lairez(5)